It’s been more than ten years since the FDA signed off on the United States’ first biosimilar product, opening up what was ...

Samsung Bioepis reviews Organon acquisition to boost direct biosimilar sales Samsung Bioepis explores direct sales expansion ...

As drug pricing pressure intensifies and benefit structures shift, some health systems are still treating biosimilars as a selective cost lever — deploying them in certain payer segments while ...

Alvotech has a current portfolio of eight products and product candidates targeting autoimmune disease, eye disorders, respiratory disease, and cancer. The company has successfully launched its ...

The Biologics Price Competition and Innovation Act of (BPCI Act) of 2009 granted responsibility to the FDA for review and approval of a new class of pharmaceuticals referred to as “Biosimilars.” (1) ...

The study of postmenopausal women in Iran found the efficacy of the biosimilar was noninferior to the reference product and the safety was comparable after 18 months. As the global population ...

Credit: Getty Images. Rezvoglar may now be substituted for Lantus at the pharmacy counter without the need for an intervention from the prescriber. The Food and Drug Administration (FDA) has approved ...

On paper, biosimilars have great potential to cut development costs, expand patient access to biologics, and improve affordability. The practical reality is that these goals are difficult to achieve.

--Analysis of Pivotal Trial Results of Insulin Glargine Nearly Completed, BLA Filing Timeline Slightly Delayed, But Potential Launch Timing Remains in Range-- TREVOSE, Pa., Jan. 4, 2023 /PRNewswire/ - ...